PPBT

Purple Biotech Ltd

• Reuters·4h ago

  Purple Biotech director Suzana Zilberberg files initial beneficial ownership statement

• Reuters·1d ago

  Purple Biotech files Form 3 as director Ido Agmon reports beneficial ownership

• Reuters·6d ago

  Purple Biotech CEO Gil Efron files initial beneficial ownership statement

• Reuters·03/30 20:12

  Purple Biotech Head of Clinical, Reg Affairs Schickler files initial beneficial ownership statement

• Reuters·03/27 16:10

  Purple Biotech files initial beneficial ownership statement; Director Shai Lankry reports 3.55 million ordinary shares

• TipRanks·03/25 12:32

  Purple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform

• TipRanks·03/25 12:17

  Purple Biotech announces collaboration with Converge Bio

• Reuters·03/25 12:04

  Purple Biotech partners with Converge Bio; collaboration expands AI-driven tri-specific antibody development platform

• Benzinga·03/25 12:02

  Purple Biotech Partners With Converge Bio Over Tri-Specific Antibody Platform

• Reuters·03/25 12:00

  PURPLE BIOTECH ANNOUNCES AI COLLABORATION WITH CONVERGE BIO TO ACCELERATE DEVELOPMENT OF ITS NEXT-GENERATION TRI-SPECIFIC ANTIBODY PLATFORM

• TipRanks·03/20 13:30

  Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)

• TipRanks·03/20 06:01

  Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

• TipRanks·03/19 12:42

  Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones

• Reuters·03/18 22:07

  Purple Biotech Director Robert E. Gagnon Files Initial Beneficial Ownership Statement

• Reuters·03/17 11:04

  Purple Biotech regains Nasdaq compliance with $1 minimum bid price rule